TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41431

Peptide_Name

C7A

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF pep-lab

Sequence_Type

standard

Has_Modification No

Description A 27-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

KILRGVAKKILRTFLRRISKDILTGKK-NH2

FASTA

>TPDB41431|Anticancer|length=27
KILRGVAKKILRTFLRRISKDILTGKK-NH2

Formula C144H263N45O33

Absent Amino Acids NCEQHMPWY

Common Amino Acids K

Mass 3152.95

PI 12.43

Basic Residues 10

Acidic Residues 1

Hydrophobic Residues 11

Net Charge +9

Boman Index 6.13

Hydrophobicity -0.219

Aliphatic Index 130.00

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 3

number

1

A

4

R

0

N

1

D

0

C

0

E

0

Q

2

G

0

H

4

I

4

L

6

K

0

M

1

F

0

P

1

S

2

T

0

W

0

Y

1

V

Amino Acid Distribution

A: 1 R: 4 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 4 L: 4 K: 6 M: 0 F: 1 P: 0 S: 1 T: 2 W: 0 Y: 0 V: 1

Length

27

Formula

C144H263N45O33

Mass

3152.95

PI

12.43

Net Charge

+9

Boman Index

6.13

Hydrophobicity

-0.219

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

NK-2 variants

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 10.6±0.4 µM

Detail Source Activity Anticancer

Activity Measurement 10.6

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 30-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 13.0±1.0 µM

Detail Source Activity Anticancer

Activity Measurement 13.0

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 2-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 12.1±1.6 µM

Detail Source Activity Anticancer

Activity Measurement 12.1

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 3.7± 4.3 µM

Detail Source Activity Anticancer

Activity Measurement 3.7

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013